Use of Rozanolixizumab for Myelin Oligodendrocyte Glycoprotein Antibody
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3, PIVOTAL STUDY WITH AN OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PARTICIPANTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) ANTIBODY
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Brain and Nervous System, Myelin-Oligodendrocyte Glycoprotein
Study Purpose
The purpose of MOG001 is to assess how safe, tolerable (acceptable to you) and effective rozanolixizumab (referred to as 'the study drug' hereafter) is in treating MOG-AD. This study will also help us understand how it acts in your body and how your body reacts to it in MOG001.
Who Can Participate
Age: 18- 89 years old
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
- UH IRB: SITE00001964
- StudyID: 2023-01162
- ClinicalTrials.gov: NCT05063162
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422